上腺系统与肥胖之间的相互作用:一个系统性审查
Beatriz Araújo1,2, Fernanda Leite1,3,4, Laura Ribeiro5,6
1Department of Public Health and Forensic Sciences, and Medical Education, Medical Education Unit, Faculty of Medicine of the University of Porto, Porto, Portugal.
International journal of obesity (2005)
|October 11, 2025
概括
患有肥胖症的人表现出高上腺体状态,上腺素和上腺素水平发生变化,并减少了同情反应. 减肥干预可以改善这些上腺功能失调.
科学领域:
- 内分泌学 在内分泌学.
- 代谢障碍 代谢障碍 代谢障碍
- 神经科学是一个神经科学.
背景情况:
- 肥胖是一个重大的全球健康挑战.
- 交感神经系统 (SNS) 失调,特别是涉及上腺系统,与肥胖的发展有关.
- 了解上腺系统的作用对于肥胖研究至关重要.
研究的目的:
- 系统地审查有关上腺系统参与肥胖的文献.
- 为了探索catecholamine水平和肥胖之间的关系.
- 确定该领域的研究缺口.
主要方法:
- 在PubMed,Web of Science和Scopus数据库中进行了全面的搜索.
- 包括2023年6月之前发表的研究,重点关注肥胖成年人的血或尿上腺素和上腺素.
- 布尔式搜索词包括"肥胖/肥胖"和"上腺素/上腺素/上腺素/上腺素/上腺素".
主要成果:
- 35项涉及2588名受试者的研究符合纳入标准.
- 有证据表明,肥胖症的高上腺体状态,高上腺素和降低上腺素.
- 肥胖相关的并发症,不包括高血压,加剧上腺素过量;减肥干预改善SNS反应.
结论:
- 上腺系统和肥胖症之间有着密切的联系,涉及复杂的甲醇胺相互作用.
- 本综述综合了当前关于肥胖症上腺激素失调的证据.
- 结果为未来的研究和肥胖管理中的临床策略提供了洞察力.
相关概念视频
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
166
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
166
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
246
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
246
Drug Dosing: Obese Patients
222
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
222
Adrenergic Receptors: β Subtype
3.5K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.5K
Adrenergic Receptors (Adrenoceptors): Classification
4.6K
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
4.6K


